title: [Protective efficacy of BCG Tokyo 172 in the guinea pig model of pulmonary tuberculosis].
abstract: BCG Tokyo 172 strain was examined for its protective efficacy against pulmonary tuberculosis in a guinea pig model. Guinea pigs were vaccinated with an intradermal injection of 10(3) CFU of BCG Tokyo 172 strain. BCG Copenhagen 1331 was employed as a control strain. Eight weeks after the vaccination, the animals were infected with about 10 CFU of M. tuberculosis H37Rv by a respiratory route in an aerosol chamber. Five weeks after infection, the animals were euthanized and their spleens, lungs and livers were obtained for enumeration of M. tuberculosis H37Rv and histopathological examinations. The mean log10 CFU of M. tuberculosis H37Rv recovered from right lower lung lobes of guinea pigs vaccinated with BCG Tokyo 172 (frozen), BCG Tokyo 172 (freeze-dried), BCG Copenhagen 1331 (freeze-dried) and placebo were 4.72, 4.23, 4.35 and 5.76, respectively. The mean log10 CFU of the bacteria recovered from spleens were 2.11, 1.51, 1.37 and 5.90, respectively. There was a significant difference in bacterial recovery from both lung and spleen between the vaccinated and the non-vaccinated groups. No significant difference was seen among the groups vaccinated with different strains of BCG in any organ. The lungs exhibited just small granulomatous nodules and the spleens showed no granulomatous nodules in the BCG-vaccinated guinea pigs. On the other hand, the lungs and spleens from non-vaccinated guinea pigs showed much larger granulomatous nodules with central necrosis. These histopathological difference between the vaccinated and the non-vaccinated guinea pigs was consistent with the difference of bacterial growth between them. The results of this study have clearly indicated that BCG Tokyo 172 strain possesses a significant protective efficacy against M. tuberculosis as well as BCG Copenhagen 1331 strain. These results have also shown that the respiratory infection model in guinea pigs is very useful to evaluate efficacy of vaccines against pulmonary tuberculosis.
authors.affiliation: Dept. Bacterial & Blood Products, National Institute of Infectious Diseases, Tokyo, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Yamamoto
authors.forename: S
authors.initials: S
authors.lastname: Phalen
authors.forename: K
authors.initials: K
authors.lastname: Uchida
authors.forename: K
authors.initials: K
authors.lastname: Umemori
authors.forename: Y
authors.initials: Y
authors.lastname: Nojima
authors.forename: Y
authors.initials: Y
authors.lastname: Horiuchi
authors.forename: Y
authors.initials: Y
authors.lastname: Goto
authors.forename: D N
authors.initials: DN
authors.lastname: McMurray
authors.forename: S
authors.initials: S
authors.lastname: Yamamoto
mesh_terms: D000818:Animals; D001500:BCG Vaccine; D004195:Disease Models, Animal; D005260:Female; D006168:Guinea Pigs; D008297:Male; D014397:Tuberculosis, Pulmonary / Q000517:prevention & control*; D014613:Vaccines, Attenuated
chemical_list: D001500:BCG Vaccine; D014613:Vaccines, Attenuated